Integrated Filing- Financial

Balaxi Pharmaceuticals Limited has announced a board meeting to review the financial results for the quarter and nine months ended December 31, 2024. The standalone revenue from operations decreased to ₹11.16 crore compared to ₹12.70 crore in the previous year, while total income rose slightly to ₹14.07 crore.

Net profit for the quarter improved to ₹1.74 crore from ₹0.49 crore year-on-year.

The consolidated results reflected a revenue of ₹73.29 crore, showing significant growth from ₹60.78 crore last year, with net profit at ₹5.36 crore.

This solid performance may foster a positive outlook among investors, reflecting operational resilience despite market challenges.